Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 272 results

M&A: Year of the megadeal

UK, US30-09-2019

LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.

IP portfolios: the five biggest headaches for in-house counsel

International30-09-2019

In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.

Secondary patents: Moscow mewl

Russia30-09-2019Maxim Sobolev

An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Stobolev of Rouse.

CRISPR: Hearing all about it

UK30-09-2019Catherine Coombes and Emma Longland

There is no doubting the importance of next year’s CRISPR appeal, but any conclusions about the parties’ prior art have consequences for elsewhere too, say Catherine Coombes and Emma Longland of HGF.

Dosage patents: Down the hatch

UK30-09-2019Richard Wells and Stephanie Pilkington

The Actavis v ICOS UK supreme court judgment was a bitter pill to swallow, but is it really the end of dosage patents? Richard Wells and Stephanie Pilkington of Potter Clarkson review the situation.

Divisional applications: Procedural manoeuvres pay off

Brazil30-09-2019Kene Gallois and Luis Felipe Maciel da Silva

Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.

Conference preview: BioPharm America 2019

US10-09-2019Guadalupe Rodriguez

Held during Boston’s week-long Biotech festival, BioPharm America promises its 4,500 delegates excellent knowledge, networking, and deal opportunities, says Guadalupe Rodriguez of EBD Group.

The future of precision medicine part 7: public engagement

International29-08-2019Daniel Lim

For all the importance of the role of government and private sector bodies in the realisation of precision medicine, it’s important not to lose sight of the interests and concerns of those precision medicine intends to treat—the patients and public at large, write Daniel Lim and Anna Jackson of Kirkland & Ellis.

The future of precision medicine part 6: reimbursement

International08-08-2019Daniel Lim

In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.

The future of precision medicine part 5: keeping pace with regulation

International26-07-2019Daniel Lim

One of the perennial inherent challenges for legislators and regulators is crafting laws and regulatory frameworks that are firm enough to deal with the issues of the present, but flexible enough to cater for the challenges of the future, as Daniel Lim and Anna Jackson of Kirkland & Ellis explain.

Showing 1 to 10 of 272 results

LSIPR